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Some recent clinical developments allow the extension of hematopoietic stem cell transplantation (HSCT) to elderly patients. 1 Reduced-intensity conditioning (RIC) regimen-based HSCT was introduced for these patients. Although various RIC regimens have been used and subsequently reported, the high treatment-related toxicity, early mortality and lower survival rate of elderly recipients remain unresolved. Several groups have reported that conditioning regimens employing fludarabine plus melphalan (FM) are efficacious and well tolerated. 2, 3 We previously investigated the appropriate melphalan dose in combination with fludarabine in a prospective phase 1 study, 4 and our findings led us to recommend a melphalan dose of ⩾ 135 mg/m 2 to induce initial full-donor chimerism. Although another group reported that melphalan administered to elderly patients at doses up to 180 mg/m 2 is safe and efficacious, 5 most of these reports included a wide range of melphalan doses. The optimal melphalan dose combined with fludarabine for elderly patients is still unclear.
We performed a retrospective, multicenter analysis. Data were provided by the Nagoya Blood and Marrow Transplantation Group, and the registry data were managed using the Transplant Registry Unified Management Program. 6 Between April 2002 and March 2011, 371 elderly patients aged ⩾ 55 years underwent their first allogeneic HSCT at nine Nagoya Blood and Marrow Transplantation Group-affiliated hospitals. We included 113 patients with AML, ALL/lymphoblastic lymphoma and myelodysplastic syndrome who fulfilled the following criteria: the conditioning regimen included fludarabine (125 mg/m 2 ) and melphalan (130-180 mg/m 2 ; FM). GvHD prophylaxis was either cyclosporine or tacrolimus (Tac), which was combined with a short course of methotrexate (MTX). The grafts comprised either bone marrow or granulocyte CSF-mobilized PBSC. Patients receiving TBI or undergoing in vivo or ex vivo T-cell depletion were excluded. We compared two groups according to melphalan dose as follows: FM 160-180 (melphalan 4140 mg/m 2 ) and FM 130-140 (melphalan ⩽ 140 mg/m 2 ) based on the Center for International Blood and Marrow Transplant Research criteria, which define melphalan ⩽ 140 mg/m 2 as RIC regimens. 7 The disease risk was defined according to the disease risk index, which combined cytogenetic risk and stage risk. 8 Acute GvHD was classified according to clinical criteria, 9 and chronic GvHD was graded as limited or extensive. 10 The Institutional Review Board approved this study, which was conducted in accordance with the Declaration of Helsinki. Supplementary Table 1 lists the main characteristics of patients. In brief, FM 160-180 patients had higher disease risk, transplantation during the preceding year, and they were more likely to receive stem cells from unrelated donors, bone marrow transplantation and Tac-based GvHD prophylaxis. In contrast, FM 130-140 patients more frequently received stem cell transplants from HLA-matched donors. The median follow-up period for all survivors was 833 days (range, 104-1925 days), and the 2-year overall survival (OS) was 46.7%. OS was higher for FM 130-140 Letter to the Editor patients (57.7%) than FM 160-180 patients (37.8%, P = 0.032; Figure 1a ). Figure 1b ). There was no statistically significant difference according to conditioning regimen between the OS of patients with low/intermediate risk disease (57.3% vs 67.6%, P = 0.30) and high/very high-risk disease (27.0% vs 40.0%, P = 0.35; Figure 1c ). Focusing on highand very high-risk patients, the relapse rate was not significantly different between the groups (P = 0.073). In this subgroup, the cumulative incidences of relapse at 2 years were 29.7% and 11.1% in FM 160-180 and FM 130-140 patients, respectively. In this study, of the patients surviving ⩽ 30 days after HSCT, 108/111 (97%) had neutrophil counts 40.5 × 10 9 /L. The median period to neutrophil recovery was 16 and 17 days, and neutrophil recovery rates on day 21 were 79.7% and 92.6% for FM 160-180 and FM 130-140 patients, respectively (P = 0.058). The cumulative incidences of acute and chronic GvHD were not statistically different between the groups. The incidences of grades 3 to 4 acute GvHD on day 100 were 14.8% and 12.0%, respectively (P = 0.74). Chronic GvHD incidences at 2 years were 22.5% and 37.9% for FM 160-180 and FM 130-140 patients, respectively (P = 0.46), and those of extensive chronic GvHD at 2 years were 15.6% and 29.4%, respectively (P = 0.41).
These results indicate that melphalan dose escalation is not beneficial for decreasing the relapse rate in elderly patients. At first, we hypothesize that the difference in OS between the two groups is similar, because the FM 130-140 group would have a higher relapse rate and the FM 160-180 group would have a higher rate of treatment-related mortality. However, the NRM data of both groups were similar, and the FM 160-180 group had a significantly higher relapse rate. Consequently, the FM 130-140 group experienced longer OS. However, even in the high-risk subgroup, the two conditioning regimen groups had similar relapse rates.
Reduction of conditioning intensity is associated with lower engraftment rates and a lower incidence of post-transplant complications and mortality. 11 In the present study, however, neutrophil recovery and NRM incidence were not significantly different between the FM 130-140 and FM 160-180 groups. This may have occurred because patients in the FM 130-140 group received more PBSCs than those in the FM 160-180 group. We reported previously that 135 mg/m 2 of melphalan is an optimal dose in combination with 125 mg/m 2 of fludarabine, using engraftment and day 100 mortality as end points for elderly patients who underwent unrelated bone marrow transplantation. 4 A phase 2 study reported by Bashir et al. 12 showed that dose escalation was not beneficial for improving progression-free survival. The results of the present study are consistent with these findings, and we therefore suggest that FM 130-140 is a suitable conditioning regimen for elderly patients.
Regarding factors other than conditioning regimens, multivariate analysis revealed that HSCT from a female donor to a male recipient and MTX-combined Tac-based GvHD prophylaxis were statistically significant risk factors for NRM ( Table 1) . The latter was a statistically significant risk factor for OS as well. Gahrton et al. reported that the combination of female donor and male recipient was a significant risk factor for increased NRM and overall mortality. 13 Our present results are consistent with this. In contrast, the higher risk of decreased survival of patients who received MTX-combined Tacbased GvHD prophylaxis is difficult to explain. Between the two GvHD prophylaxis groups, the cumulative incidence of GvHD is not different (grade 2-4 acute GvHD: P = 0.22, chronic GvHD: P = 0.25). Furthermore, Tac-related complications such as bacterial infection (P = 0.78) and thrombotic microangiopathy (P = 0.96) were also similar between the two groups. These results may be explained by age-specific factors such as differences in drug metabolism, 14, 15 but further research is needed.
We recognize that our study has certain limitations related to the optimal melphalan dose, mainly because of its retrospective design and the small number of patients included. The melphalan dosage seems to have impact not on OS but on relapse rate by the multivariate analysis. The confounding factors cannot be removed completely. Further prospective studies are required to define with certainty the optimal conditioning regimen for elderly patients who receive HSCT.
